SCHEMBL8723972

SCHEMBL8723972

CC=CCCOC(=O)Nc1ccc2scc(C3CCC4CCCCN4CC3)c2c1

nearest known ligand 0.35

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 4/20 0.35
HTR1D P28221 9/20 0.34
HTR1B P28222 9/20 0.34
SHMT2 P34897 1/20 0.33
ALDH1A1 P00352 1/20 0.33
KCNH2 Q12809 1/20 0.32
MCHR1 Q99705 1/20 0.32
TSHR P16473 1/20 0.32
HTT P42858 1/20 0.32
DRD2 P14416 1/20 0.32
SLC6A4 P31645 1/20 0.32
TP53 P04637 1/20 0.32
HPGD P15428 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8721866 0.86 TP53 (0.38) HRH3HTR1DHTR1BSHMT2ALDH1A1
SCHEMBL8720869 0.82 ACHE (0.39) HRH3HTR1DHTR1BSHMT2MEN1
SCHEMBL8723639 0.81 KDM4E (0.40) HRH3HTR1DHTR1BALDH1A1KCNH2
SCHEMBL8721868 0.80 HRH3 (0.34) HRH3HTR1DHTR1BSHMT2ALDH1A1
SCHEMBL8721056 0.80 MCHR1 (0.38) HRH3KCNH2MCHR1TP53
SCHEMBL8725933 0.80 HTR1D (0.45) HRH3HTR1DHTR1BSHMT2ALDH1A1
SCHEMBL8725999 0.79 CHRNA7 (0.42) HRH3SHMT2KCNH2MCHR1TP53
SCHEMBL8721062 0.78 LMNA (0.43) HRH3HTR1DHTR1BTSHRHPGD
SCHEMBL8725936 0.78 SHMT2 (0.37) HRH3HTR1DHTR1BSHMT2ALDH1A1
SCHEMBL8725928 0.77 RORC (0.47) HRH3HTR1DHTR1BTP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125645-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS VALORISATION HSJ LP (CA) 2026-05-07 US disclosed
WO-2024073845-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS VALORISATION HSJ, LIMITED PARTNERSHIP (CA) 2024-04-11 WO disclosed
EP-0875513-A1 Substituted heteroaromatic 5-HT 1F agonists ELI LILLY AND COMPANY (US) 1998-11-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125645-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS HTR1F, HTR1A, HTR1D HRH3 126/4885HTR1D 3/4885HTR1B 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.